Enhanced antitumor activity of irofulven in combination with antimitotic agents

Investigational New Drugs

Volumn 20, Issue 3, 2002, Pages 271-279

  Kelner, Michael J ^a   McMorris, Trevor C ^b   Rojas, Rafael J ^a   Trani, Nicole A ^a   Velasco, Tami R ^a   Estes, Leita A ^a   Suthipinijtham, Pharnuk ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

Irofulven; Taxol; Taxotere; Vinblastine; Vincristine; Vinorelbine

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ALLOCOLCHICINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CYSTEINE DERIVATIVE; DOCETAXEL; IROFULVEN; NAVELBINE; NSC 406042; NSC 608210; PACLITAXEL; RHIZOXIN; S TRITYLCYSTEINE; TAXANE DERIVATIVE; TRITYL DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE SULFATE; VINCA ALKALOID; VINCRISTINE SULFATE; 3 TRITYLTHIOALANINE; 3-TRITYLTHIO-L-ALANINE; ANTINEOPLASTIC ANTIBIOTIC; BRIDGED COMPOUND; COLCHICINE; CYSTEINE; DRUG DERIVATIVE; LACTONE; MACROLIDE; SESQUITERPENE; TAXANE; TAXOID; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; METABOLISM;

ANIMAL; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CELL SURVIVAL; COLCHICINE; CYSTEINE; DRUG SYNERGISM; FEMALE; LACTONES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; SESQUITERPENES; SUPPORT, NON-U.S. GOV'T; TUBULIN; TUMOR CELLS, CULTURED; VINCA ALKALOIDS; ANIMALS; MACROLIDES; TAXOIDS;

EID: 0036021223     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016201807796     Document Type: Article

References (35)

1. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents
2. Preclinical evaluations of illudins as anticancer agents
3. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S
4. Activity of irofulven (6-hydroxymethylacylfulvene, MG1-114) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice
5. In vivo antitumor efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric turnouts
6. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft
7. Efficacy of MGI 114 against the MRP+ metastatic MV 522 lung carcinoma xenograft
8. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)
9. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells
10. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF)
11. Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression
12. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
13. Phase II study of irofulven in platinum resistant recurrent ovarian cancer
14. Phase II trial of Irofulven (MGI 114) in patients with advanced pancreatic cancer who have progressed on gemcitabine
15. Irofulven monotherapy: Impressive phase I and II clinical antitumor activity in heavily treated patients
16. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model
17. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model
18. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with Topotecan
19. MGI 114: Augmentation of antitumor activity when combined with topotecan
20. Antitumor activity of irofulven (MGI 114) in combination with taxotere against DU145 human prostate tumor xenograft model
21. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C
22. Microscopic metastasis of a human lung carcinoma cell line in athymic nude mice: Isolation of a metastatic variant
23. The median-effect principle and the combination index for quantification of synergism and antagonism
24. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
25. Applications of median-effects principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents
26. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents
27. Use of nude mouse xenografts as preclinical drug screens: In vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts
28. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: Combining drugs imposes different artificial checkpoints
29. Caspase-3 activation is not responsible for vinblastine-induced Bcl-2 phosphorylation and G2/M arrest in human small cell lung carcinoma Ms-1 cells
30. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells
31. Caspase 3 is not required for apoptosis by irofulven (hydroxymethylacylfulvene)
32. Early events in apoptosis induced by irofulven (hydroxymethylacylfulvene) in prostate tumor cells
33. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspace-3 activity during Taxol-induced apoptosis of human AML HL-60 cells